About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
Keytruda is the first and only anti-PD-1 therapy approved in combination with chemoradiotherapy for these patients
Sarclisa added to bortezomib, lenalidomide and dexamethasone (VRd) significantly reduced the risk of disease progression or death compared with VRd alone
Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex
In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient population
Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy
If approved, KEYTRUDA would be the first immunotherapy for the first-line treatment of HER2-positive advanced gastric or GEJ cancer in tumors expressing PD-L1 (CPS ?1) in the EU
This trial is a multi-national, phase 2/3, open-label, randomized, controlled clinical study of utidelone injectable
Based on a subgroup analysis by PD-L1 expression from KEYNOTE-811, Merck is working with the US FDA to update the current indication for KEYTRUDA in HER2-positive gastric or GEJ adenocarcinoma
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
